

01-16-02

#3 1P5  
J. Scott  
3-26-02 1624  
CASE 4-30096B



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<u>EV 041586055 US</u> Express Mail Label Number	<u>1/14/02</u> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/991,184

FILED: NOVEMBER 16, 2001

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE  
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS  
USE

RECEIVED  
JAN 22 2002  
TECHNICAL CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references (A and B) are of record in parent Application No. 09/463,097 filed January 18, 2000, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, copies of the other cited references (AR and AS) are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6923

  
\_\_\_\_\_  
Gregory D. Ferraro  
Attorney for Applicants  
Reg. No. 36,134

Date: January 14, 2002

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)



**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,521,184	5/28/96	Zimmermann	514	252	
	AB	5,985,893	11/16/99	Yu et al.	514	312	
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

**RECEIVED**  
 JAN 22 2002  
 TECH CENTER 1600/2900

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Bilder et al., "Inhibitors of the Platelet-Derived Growth Factor Receptor Tyrosine Kinase" Cardiovascular Drug Reviews, Vol. 14, No. 4, pp. 380-399 (1996)
	AS	Buchdunger et al., "Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class" Proc. Natl. Acad. Sci., USA, Vol. 92, pp. 2258-2562 (1995)
	AT	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.